Search
Cellectis SA
CLLSAdd to Watchlist
2.980USD
-0.100-3.25%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
220.75MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Cellectis SA is 8.67, ranking 77 out of 389 in the Biotechnology & Medical Research industry. The average price target is 7.50, with a high of 10.00 and a low of 4.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.714
Target Price
+158.87%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Cellectis SA
CLLS
7
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Cellectis SA's expected revenue for the next quarter?
Cellectis SA's expected revenue is 14.73M.
What is Cellectis SA's price target?
Analysts forecast that Cellectis SA's price target is USD 7.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 4.00.
How have Cellectis SACLLS's recent earnings per share performed?
The market expectation was USD -0.18, while Cellectis SACLLS's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.27.
What is the analyst rating for Cellectis SA?
Based on the ratings of Cellectis SA's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
